March 12, 2020 10:23 AM EDT
News Briefing

Cure­Vac founder back at the helm; Mer­ck ex­tends im­munomod­u­la­to­ry drug dis­cov­ery pro­gram with Sutro

Amber Tong

→ Daniel Menichel­la, the CEO of Cure­Vac and the face of its re­cent en­deav­ors to de­vel­op an mR­NA vac­cine against Covid-19, is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Nether­lands pours $1.5B in­to biotech in pur­suit of glob­al lead­er­ship am­bi­tions

Ex­clu­sive: BigHat inks Lil­ly deal for AI-boost­ed an­ti­bod­ies, ex­tends Se­ries B

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times